Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Chief Commercial Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,819 |
Ending reported balance
After 2026-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 1,469 · Balance 10,354 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 535 · Balance 9,819 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,406 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Exercise / conversion · Disposed 1,469 · Balance 4,406 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 02:45 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 32,024 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-000585 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 21:50 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 235 | $1.23 | $288.02 |
DisclosureSEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,712 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:50 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 234 | $1.27 | $297.34 |
DisclosureSEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,947 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:50 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-001383 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,405 Underlying: Common Stock · 1,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:50 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 1,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-001383 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 23:28 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 849 | $1.27 | $1,075.60 |
DisclosureSEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,692 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 23:28 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 850 | $1.39 | $1,180.06 |
DisclosureSEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,541 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:28 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000666 · form4.xml · derivative · entry 5 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:28 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000666 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,894 Underlying: Common Stock · 1,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:28 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-000666 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:31 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 6,172 | $1.62 | $9,998.64 |
DisclosureSEC source: 0000905148-23-000625 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,929 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 11,564 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0000905148-23-000511 · form4.xml · derivative · entry 5 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,564 Underlying: Common Stock · 11,564 shares Expires 2033-07-23 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F5 · derivative.exercise_date: This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:14 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 31,055 | Not disclosed Strike: $20.67 | Not disclosed |
DisclosureSEC source: 0000905148-23-000511 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,055 shares Expires 2031-02-22 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:14 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 25,599 | Not disclosed Strike: $20.67 | Not disclosed |
DisclosureSEC source: 0000905148-23-000511 · form4.xml · derivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,599 shares Expires 2031-02-22 F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F4 · price: The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. Read SEC document |
| May 10, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 474 | $1.58 | $747.07 |
DisclosureSEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,757 F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,223 | $1.57 | $1,915.71 |
DisclosureSEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,231 F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023968 · form4.xml · derivative · entry 5 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,972 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F7 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023968 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,384 Underlying: Common Stock · 1,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 08, 2023 Filed May 11, 2023 00:16 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-023968 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 52,531 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010024 · form4.xml · derivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,531 Underlying: Common Stock · 52,531 shares Expires 2033-02-28 F1 · derivative.exercise_date: This option vested in full on March 1, 2023. Under the Issuer's 2022 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2022 in the form of a fully-vested option. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,999 | $1.80 | $3,596.40 |
DisclosureSEC source: 0001140361-23-006073 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,993 F2 · kind: These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006073 · form4.xml · derivative · entry 5 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,944 Underlying: Common Stock · 3,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006073 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,873 Underlying: Common Stock · 1,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 122,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006073 · form4.xml · derivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,135 Underlying: Common Stock · 122,135 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F4 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:40 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-006073 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 4,347 | $1.15 | $4,999.05 |
DisclosureSEC source: 0001140361-22-042598 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,531 Read SEC document |
| November 10, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 753 | $1.02 | $766.18 |
DisclosureSEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,184 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 952 | $1.04 | $991.79 |
DisclosureSEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,937 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041082 · form4.xml · derivative · entry 5 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,915 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041082 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,363 Underlying: Common Stock · 1,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-041082 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,673 | $2.53 | $4,229.68 |
DisclosureSEC source: 0001140361-22-029133 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,428 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029133 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,887 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029133 · form4.xml · derivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,852 Underlying: Common Stock · 1,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:53 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-029133 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| May 10, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,583 | $1.83 | $2,896.89 |
DisclosureSEC source: 0001140361-22-018736 · form4.xml · nonDerivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,639 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018736 · form4.xml · derivative · entry 4 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,859 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018736 · form4.xml · derivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,342 Underlying: Common Stock · 1,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-018736 · form4.xml · nonDerivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F6 · balance_after: Includes 1,157 and 2,604 Shares acquired under the BDSX stock purchase plan on August 31, 2021 and February 28, 2022, respectively. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 6,162 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 3 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,162 Underlying: Common Stock · 6,162 shares Expires 2032-03-09 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 4,211 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,423 Underlying: Common Stock · 4,211 shares Expires 2030-04-14 F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 4,211 shares underlying the option. F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 4,211 shares underlying the option. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:09 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 23,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004588 · form4.xml · derivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,831 Underlying: Common Stock · 23,831 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:09 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 23,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004588 · form4.xml · derivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,831 Underlying: Common Stock · 23,831 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 23, 2021 Filed Mar 14, 2022 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 4,212 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-006920 · doc1.xml · derivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,212 Underlying: Common Stock · 4,212 shares Expires 2030-04-14 F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 4,212 shares underlying the option. F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 4,212 shares underlying the option. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 31,055 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000511 · form4.xml · derivative · entry 2 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,055 Underlying: Common Stock · 31,055 shares Expires 2031-02-22 F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:14 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 25,599 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000511 · form4.xml · derivative · entry 1 O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,599 Underlying: Common Stock · 25,599 shares Expires 2031-02-22 F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.